Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psychopharmacological Treatment of Emotional Distress
NCT06133114Phase 4Withdrawn
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of clonazepam, olanzapine, buprenorphine in Suicide Crisis Syndrome (SCS), sponsored by Icahn School of Medicine at Mount Sinai. Planned start Mar 2024; status: withdrawn.
02
Drugs
clonazepamolanzapinebuprenorphine
03
Conditions
Suicide Crisis Syndrome (SCS)
Beyond the preview
Go deeper on NCT06133114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133114.